Progression for SMCI $58 next Minimum

982
The price progression for SMCI should move up exceeding168.66. This is based on the new profit margin of 13.7%. As you all know SMCI was the victim of a short raid by the Hindenburg report, and associates, and some are including Ernst and Young in the conspiracy, based on the Chairman Janet strong affinity with the Obamas and the incidental information that these two actors also were behing the Adani Group also a victim.

However, at the moment SMCI has been completely cleared of fraud has a new accountant.

Significant investments in AI infrastructure are currently underway in Europe, while the United States continues to enhance its capabilities. A notable trend is the emergence of sovereign AI, where nations seek to develop independent AI systems for automation and management. SMCI's price-to-earnings (P/E) ratio stands at 21, significantly lower than the segment's average of 57, suggesting substantial growth potential. With over 21% of shares shorted, upward momentum is expected to persist as market dynamics shift favorably.

As of December 5, 2024, Super Micro Computer Inc. (SMCI) has a trailing P/E ratio of 21.43 and a forward P/E ratio of 15.56. The current earnings per share (EPS) stands at $1.92 based on a stock price of $41.14. This valuation indicates that SMCI is trading at a relatively lower multiple compared to its sector, suggesting potential for future growth as market conditions evolve
Note
Look into CrSp = Crispr Therapeutics - they have now 2 therapies approved - that one is the next trillion dollar company... calculate the waves boys, CrSp is ready for a massive POP , but look into it, this company is the new medicine that will solve from cancer to likely immortality and inbetween, food supply shortages , hunger and all sort of ecological issues. For real. Investigate ask the AI to calculate the DCF for the stock. it is coming at $1,078 a share and trades for $41, plus it has a lot of money backer, and it is opening centers across the globe. plus has a genetic factory in the USA and it is lead by two nobel prize winners.

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.